Search results for PTXCOV-A542

Anti-2019-nCoV(S1)-1 IgM antibody, ProteoGenix, PTXCOV-A542

Description of Anti-2019-nCoV(S1)-1 IgM antibody General information on Anti2019-nCoV-(S1)-1 Proteogenix has developed neutralizing antibodies against 2019-nCOV (as named by WHO when SARS-CoV-2 begun to spread). The Anti-2019-nCoV-(S1)-1 antibody is an IgM isotype, especially targeting the S1 part of the Spike protein. This product is a human-origin monoclonal antibody expressed in a mammalian system, which has been validated in binding assays and infection assays. The molecular weight is 150 kDa. About Spike targeting The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism. Immunoglobulin M-type It is a non-specific immunoglobulin of adaptive immunity. Indeed, secretion does not require the intervention of a helper T lymphocyte. They exist in 2 structural forms in the human organism: secreted or embedded in cell membrane. If secreted, IgM are circulating as a typical pentameric structure. Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Every of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic. This product is suitable for all immunological methods. Research use only.